Keppra for Intractable Epilepsy: Effectiveness and Treatment Options
Levetiracetam (Keppra) is a broad-spectrum antiseizure medication (ASM) effective for focal-onset seizures and myoclonic/juvenile myoclonic epilepsy. Its role in intractable (drug-resistant) epilepsy—defined as failure of ≥2 appropriately chosen/ tolerated ASMs—is adjunctive.
Evidence
- Add-on levetiracetam achieves ≥50% seizure reduction in ~30–40% of refractory patients.
- Favorable pharmacokinetics: no hepatic metabolism, minimal interactions, linear kinetics.
- Side effects: behavioral (irritability, aggression), fatigue, dizziness; often dose-related.
Other Options for Drug-Resistant Epilepsy
- Additional ASMs: Lacosamide, perampanel, brivaracetam, cenobamate, stiripentol (Dravet).
- Epilepsy surgery: Resection, laser ablation, neuromodulation (VNS, RNS, DBS) for focal epilepsy with identifiable focus.
- Dietary: Ketogenic diet, modified Atkins—especially pediatric.
- Clinical trials: Novel targets (e.g., Kv7, AMPA, mTOR).
Approach
Multidisciplinary epilepsy center evaluation → tailored regimen → surgery workup if medical failure. Keppra is a valuable tool but not a universal solution for intractable epilepsy.
Neurological Disorders - Related Articles
- Guillain-Barré Syndrome Treatment: Plasmapheresis, IVIG & Critical Care Management
- Supporting a Child with Cerebral Palsy: A Comprehensive Guide
- Foot Tingling & Cramps: Causes, Symptoms & When to See a Doctor
- Mirror Movement Disorder: Understanding the Cause & Symptoms
- Parkinson's Disease: Motor Symptoms, Pathophysiology, and Management
- Brief Seizures: Absence Seizures and Sub-Second Events
- Wrist Splints: Types, Uses & How to Choose the Right One